The Batten Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Batten Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Batten Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Batten Disease and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Batten Disease by 19 companies/universities/institutes. The top development phase for Batten Disease is preclinical with 15 drugs in that stage. The Batten Disease pipeline has 19 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Batten Disease pipeline products market are: Neurogene, Recursion Pharmaceuticals and JCR Pharmaceuticals.
The key targets in the Batten Disease pipeline products market include Palmitoyl Protein Thioesterase 1, Tripeptidyl Peptidase 1, and Peroxisome Proliferator Activated Receptor Alpha.
The key mechanisms of action in the Batten Disease pipeline product include Tripeptidyl Peptidase 1 Activator with three drugs in Phase II. The Batten Disease pipeline products include seven routes of administration with the top ROA being Oral and four key molecule types in the Batten Disease pipeline products market including Small Molecule, and Gene Therapy.
Batten Disease overview
Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone, and movement problems.
For a complete picture of Batten Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
